BR112014018815A8 - Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis - Google Patents

Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis

Info

Publication number
BR112014018815A8
BR112014018815A8 BR112014018815A BR112014018815A BR112014018815A8 BR 112014018815 A8 BR112014018815 A8 BR 112014018815A8 BR 112014018815 A BR112014018815 A BR 112014018815A BR 112014018815 A BR112014018815 A BR 112014018815A BR 112014018815 A8 BR112014018815 A8 BR 112014018815A8
Authority
BR
Brazil
Prior art keywords
meningitidis
protein
immunogenic composition
polysaccharide conjugate
conjugate
Prior art date
Application number
BR112014018815A
Other languages
English (en)
Other versions
BR112014018815B1 (pt
BR112014018815A2 (pt
Inventor
Vinayak Kapre Subhash
Shankar Pisal Sambhaji
Original Assignee
Serum Inst India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst India Ltd filed Critical Serum Inst India Ltd
Publication of BR112014018815A2 publication Critical patent/BR112014018815A2/pt
Publication of BR112014018815A8 publication Critical patent/BR112014018815A8/pt
Publication of BR112014018815B1 publication Critical patent/BR112014018815B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO CONJUGADO PROTEÍNA-POLISSACARÍDEO X DE N. MENINGITIDIS. A presente invenção refere-se a uma composição imunogênica compreendendo um conjugado proteína-polissacarídeo X de N. meningitidis, onde o dito sacarídeo capsular X é derivado da cepa X de N. meningitidis selecionada de 8210 e 9601. A presente invenção refere-se ainda ao uso de um conjugado proteínapolissacaríde X de N. meningitidis, onde o dito sacarídeo capsular X é derivado da cepa X de N. meningitidis selecionada de 8210 e 9601 na preparação de uma composição imunogênica ou vacina para imunizar um hospedeiro humano contra doenças causadas por infecção de N. meningitidis.
BR112014018815-7A 2012-01-30 2013-01-29 Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis BR112014018815B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN281/MUM/2012 2012-01-30
IN281MU2012 2012-01-30
PCT/IB2013/050739 WO2013114268A1 (en) 2012-01-30 2013-01-29 Immunogenic composition

Publications (3)

Publication Number Publication Date
BR112014018815A2 BR112014018815A2 (pt) 2017-06-20
BR112014018815A8 true BR112014018815A8 (pt) 2017-07-11
BR112014018815B1 BR112014018815B1 (pt) 2022-07-12

Family

ID=54259032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018815-7A BR112014018815B1 (pt) 2012-01-30 2013-01-29 Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis

Country Status (17)

Country Link
US (1) US9198977B2 (pt)
EP (1) EP2809349B1 (pt)
JP (1) JP6042455B2 (pt)
KR (1) KR101897317B1 (pt)
CN (1) CN104302315B (pt)
BR (1) BR112014018815B1 (pt)
CA (1) CA2863178C (pt)
DK (1) DK2809349T3 (pt)
ES (1) ES2707294T3 (pt)
HU (1) HUE040914T4 (pt)
MX (1) MX354103B (pt)
PT (1) PT2809349T (pt)
RU (1) RU2634405C2 (pt)
SG (1) SG11201404447WA (pt)
SI (1) SI2809349T1 (pt)
TR (1) TR201900778T4 (pt)
WO (1) WO2013114268A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
NZ708523A (en) * 2012-11-21 2018-09-28 Serum Institute Of India Pvt Ltd Production of high yields of bacterial polysaccharides
RU2684615C2 (ru) 2013-08-24 2019-04-10 Бхарат Байотек Интернэшнл Лимитед Бактериальная вакцина и способы ее получения
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
MY187461A (en) 2015-06-08 2021-09-23 Serum Inst Of India Private Ltd Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
MY183392A (en) * 2015-07-04 2021-02-18 Bharat Biotech Int Ltd Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
RU2758090C2 (ru) * 2016-03-15 2021-10-26 Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. Новые конъюгаты полисахарида с белком и способ их получения
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
CN106397537B (zh) * 2016-10-13 2020-01-07 李红臣 一种高效快速的多糖蛋白结合疫苗纯化分析方法
EA201992636A1 (ru) * 2017-05-05 2020-04-17 Серум Инститьют Оф Индия Прайват Лимитед Способ удаления примесей из препаратов на основе бактериальных капсулярных полисахаридов
WO2019003238A1 (en) * 2017-06-27 2019-01-03 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. NOVEL MULTIVALENT VACCINE COMPOSITION CONTAINING POLYSACCHARIDE - PROTEIN CONJUGATES AND FORMULATION THEREOF
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
MXPA03000198A (es) * 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
ATE506963T1 (de) * 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
AU2006286228A1 (en) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
CA2808919C (en) * 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
US9044517B2 (en) * 2009-12-17 2015-06-02 Fina Biosolutions, Llc Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
SG11201407440WA (en) * 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate

Also Published As

Publication number Publication date
HUE040914T4 (hu) 2019-05-28
CN104302315A (zh) 2015-01-21
CA2863178A1 (en) 2013-08-08
JP6042455B2 (ja) 2016-12-14
EP2809349A4 (en) 2015-08-26
EP2809349A1 (en) 2014-12-10
RU2014134288A (ru) 2016-03-20
RU2634405C2 (ru) 2017-10-26
PT2809349T (pt) 2019-02-01
BR112014018815B1 (pt) 2022-07-12
EP2809349B1 (en) 2018-12-19
MX2014009250A (es) 2015-03-19
KR101897317B1 (ko) 2018-09-11
SI2809349T1 (sl) 2019-03-29
ES2707294T3 (es) 2019-04-03
US20140377302A1 (en) 2014-12-25
MX354103B (es) 2018-02-13
TR201900778T4 (tr) 2019-02-21
BR112014018815A2 (pt) 2017-06-20
US9198977B2 (en) 2015-12-01
JP2015509111A (ja) 2015-03-26
WO2013114268A1 (en) 2013-08-08
DK2809349T3 (da) 2019-02-18
CA2863178C (en) 2021-04-06
KR20140123553A (ko) 2014-10-22
CN104302315B (zh) 2018-02-06
SG11201404447WA (en) 2014-08-28

Similar Documents

Publication Publication Date Title
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
BR112013006396A2 (pt) composições imunogênicas
BR112018016755A2 (pt) vacina contra o vírus da zica
BRPI0607374A2 (pt) vacinas de vesìculas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
BR122021023687A8 (pt) Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
BRPI0620193B8 (pt) composição imunogênica e vacina a compreendendo, bem como processo para preparar a vacina
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112018000087A2 (pt) composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
BR112013005427A2 (pt) composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica.
BRPI0813307B8 (pt) composição imunogênica, vacina, e, processo para fabricar a vacina
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BRPI0907087A2 (pt) ácidos nucleicos de fórmula (i) (nuglxmgnnv)a e derivados dos mesmos como um agente imunoestimulante/adjuvante
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
BR112015001313A2 (pt) composições de vacina
NO20090062L (no) Influensavaksine
WO2013098655A9 (en) Vaccines directed against human enteroviruses
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
BR112015008418A2 (pt) uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
BR112013026661A2 (pt) método de entrega de vacina
BR112012029304A2 (pt) copolíme-ros em bloco de polissiloxano e seu uso em formulações cosmeticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2013, OBSERVADAS AS CONDICOES LEGAIS